Literature DB >> 11045270

Impact of introduction of continuous ambulatory peritoneal dialysis on blood pressure: analysis of 24-hour ambulatory blood pressure.

J Shoda1, H Nakamoto, H Okada, H Suzuki.   

Abstract

Introduction of continuous ambulatory peritoneal dialysis (CAPD) induces a variety of hemodynamic changes in patients with end-stage renal failure. Among them, blood pressure (BP) control is likely to be the most important in determining long-term survival. The aim of our study was to use 24-hour ambulatory blood pressure monitoring (24 ABPM) to evaluate the previous and present BP status of patients on CAPD. We studied 18 non diabetic hypertensive patients who were introduced onto CAPD. At least 3-6 months before the introduction of CAPD, recordings of 24 ABPM were obtained. These recordings were then compared to others obtained 2-3 months after the introduction of CAPD. The average BP was higher before CAPD than after (160/91 +/- 10/5 mmHg vs 154/88 +/- 6/3 mmHg, p < 0.01). In addition, the doses and number of antihypertensive drugs used by the patients were reduced. Analysis of 24 ABPM revealed BP reduction predominantly in the daytime and less in the nighttime after introduction of CAPD. These results indicate that introduction of CAPD cannot reduce susceptibility of cardiovascular events, because nocturnal elevation of BP remains unchanged. We are therefore reminded that, after introduction of CAPD, casual BP measurements confined to the daytime may underestimate cardiovascular risk.

Entities:  

Mesh:

Year:  2000        PMID: 11045270

Source DB:  PubMed          Journal:  Adv Perit Dial        ISSN: 1197-8554


  2 in total

1.  The management of hypertension in hemodialysis and CAPD patients.

Authors:  M Malliara
Journal:  Hippokratia       Date:  2007-10       Impact factor: 0.471

2.  Blood pressure profile in continuous ambulatory peritoneal dialysis patients.

Authors:  Rizna Abdul Cader; Halim Abdul Gafor; Rozita Mohd; Suriani Ibrahim; W H Wan Haslina; Arba'iyah Bain; Norella Ct Kong
Journal:  EXCLI J       Date:  2012-03-28       Impact factor: 4.068

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.